Vivus promotes COO to president Nov 8, 2009
Tam, who was also director of clinical and corporate development and who held several other jobs in 16 years of work at Mountain View-based Vivus, will also now work on the company s board of directors. Before Vivus hired him in 1993, Tam worked at and at (NASDAQ: XOMA) ... He d been COO at Vivus since January. (San Francisco Business Times, CA)
Amylin signs weight-loss drug deal with Takeda Nov 3, 2009
Vivus Inc. said patients taking its potential weight-loss drug Qnexa lost about 11 percent of their body weight. Arena Pharmaceuticals Inc. said patients taking lorcaserin lost 31 percent of their excess body weight in the first year of a two-year study. (Yahoo News -- Pharmaceutical Industry News)
Arena Pharma rises on new lorcaserin trial data Nov 1, 2009
Competitor Orexigen Therapeutics Inc. also presented trial data on its obesity drug candidate Contrave at the meeting, and Vivus Inc. is scheduled to make a presentation about its drug Qnexa. Related Searches. (Yahoo News -- Pharmaceutical Industry News)
Arena Pharma rises on new lorcaserin trial data Oct 27, 2009
Competitor Orexigen Therapeutics Inc. also presented trial data on its obesity drug candidate Contrave at the meeting, and Vivus Inc. is scheduled to make a presentation about its drug Qnexa. Related Searches. (Yahoo News -- Pharmaceutical Industry News)
New Diet Drugs In the Pipeline Oct 23, 2009
At least three new prescription diet drugs are in the final stages of development as pharmaceutical companies race to see which one will have the next big diet medication to hit the market. Some hopeful news from the research: Obese patients who took one of the medications along with cutting calories and exercising lost about 15% of their starting weight in a year. (13WMAZ.com, GA)
3 new diet drugs may soon help obese Oct 23, 2009
Oct. 22, 2009 09:35 AM USA Today. At least three new prescription diet drugs are in the final stages of development as pharmaceutical companies race to see which one will have the next big diet medication to hit the market. (AZCentral -- Business)
3 new prescription diet drugs may soon help obese Oct 22, 2009
Pedestrians walk across the street near Times Square in New York. About two-thirds of American adults are overweight or obese, putting them at an increased risk for diabetes, hypertension, heart disease, osteoarthritis, stroke, gallbladder disease, sleep apnea, respiratory problems and even some cancers. (USA Today -- News)
Arena obesity drug falls short against other meds Sep 20, 2009
However lorcaserin did not match the effectiveness of Orexigen Therapeutics Inc.'s drug Contrave and Vivus Inc.'s Qnexa. Those companies reported late-stage study results earlier this year. (Yahoo News -- Pharmaceutical Industry News)
Arena weight-loss trial disappoints investors Sep 19, 2009
Two other small companies, Vivus Inc (VVUS.O) and Orexigen Therapeutics Inc (OREX.O), are also close to filing for regulatory approval of new obesity drugs. Vivus shares were up 11 percent on Friday. (Yahoo News -- Pharmaceutical Industry News)
VIVUS Announces Pricing of Public Offering of Common Stock Sep 18, 2009
Sept. 17 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: ) announced today the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $10 ... All of the shares in the offering are being sold by VIVUS. ... VIVUS anticipates using the net proceeds from the offering to fund its research and development efforts, including manufacturing activities and clinical trials for its proprietary product candidates and investment in select pre-commercial... (PR Newswire)
Two Old Drugs, One New Diet Pill Sep 11, 2009
Patients taking a novel diet drug that combines the stimulant phentermine with the anticonvulsant topiramate lost an average of 37 pounds over a year with significant improvement in a number of heart risk factors, according to an announcement Vivus, the developer of the drug. In a trial known as EQUIP, which involved more than 1,200 morbidly obese patients, patients who. (ABC News)
Vivus swings to $13.2M loss in Q2 Aug 12, 2009
Mountain View-based Vivus (NASDAQ:VVUS) said the loss was primarily due to a decrease in license and other revenue as a result of deferred license revenue with K-V Pharmaceutical. Revenue was $14. (San Jose Business Journal, CA)
Experimental obesity drug showing promise Jul 21, 2009
Its rivals, Arena Pharmaceuticals Inc. and Vivus Inc., also are trying to bring their own obesity drugs to market. Orexigen said the data show Contrave is safe. (MSNBC -- Health)
Big pharma's hunt for the big O May 1, 2009
She interviews squirming marketing executives from pharmaceutical giant Vivus Inc.; a man who fruitlessly patents the Orgasmatron (a device inserted into the spine), and a vintage-vibrator collector who points out this isn't the first time the medical world has been perplexed by female desire or the lack of it ... You started this film nine years ago, when you were hired by Vivus to edit pornography that they were going to use in research to develop a Viagra equivalent for women ... Vivus had... (Globe and Mail)
Vivus swings to $6.7M Q4 loss Mar 10, 2009
Mountain View-based Vivus (NASDAQ:VVUS) said the loss was due to an increase in operating expenses of $12. 1 million and a $4. (San Jose Business Journal, CA)
VIVUS Announces Date of Fourth Quarter and Full Year 2008 Financial Results and Conference Call Mar 6, 2009
March 5, 2009 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NasdaqGM: - ), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that it will report financial results for the quarter and year ended December 31, 2008 after the NASDAQ Market closes on Monday, March 9, 2009 ... A webcast replay will be available on the VIVUS web site for 30 days ... VIVUS is a biopharmaceutical company developing innovative,... (Primezone Releases)
Obesity drugs in development face challenging regulatory environment for FDA approval Feb 10, 2009
Obesity compounds in late-stage development by Amylin Pharmaceuticals, Arena, Orexigen Therapeutics and Vivus, will likely face a challenging regulatory environment this year, physicians told Pharmawire ... Timothy Morris, CFO of Vivus Pharmaceuticals, a firm developing a proprietary obesity therapeutic called Qnexa, said he agreed that safety will be very important ... This is the rationale behind Vivuss Qnexa and Orexigens Contrave, two obesity therapies in development that combine two... (FT.com -- Markets)
